Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus: genotype 4 infection: a randomized study.
Fiche publication
Date publication
novembre 2019
Journal
Liver international : official journal of the International Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Asselah T, Pol S, Hezode C, Loustaud-Ratti V, Leroy V, Ahmed SNS, Ozenne V, Bronowicki JP, Larrey D, Tran A, Alric L, Nguyen-Khac E, Robertson MN, Hanna GJ, Brown D, Asante-Appiah E, Su FH, Hwang P, Hall JD, Guidoum A, Hagen K, Haber BA, Talwani R, Serfaty L
Lien Pubmed
Résumé
Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in North Africa and the Middle East, particularly in Egypt. This study evaluated the safety and efficacy of elbasvir/grazoprevir administered for 8 and 12 weeks in participants with HCV genotype (GT)4 infection.
Mots clés
hepatitis C, randomized controlled trial, therapeutics
Référence
Liver Int.. 2019 Nov 25;: